Numbers first: 36 mg · orforglipron.
I can predict the outcome but I cannot explain it, which means I will get the next case wrong.
I would like to know how confident the field actually is about this.
So what is the mechanism, and how well established is it?
Two administrations of 18 mg instead of one of 36 mg — the same 36 mg a week either way. Total weekly exposure is unchanged; what changes is the peak-to-trough ratio, and for an agent with a half-life measured in days the trough barely moves because the dosing interval is already short relative to it. The arithmetic is the easy part: 36 ÷ 2 = 18. Whether it is worth doing is a pharmacokinetic question, and nothing here is medical advice.
The short version: pharmacokinetically defensible for shorter half-lives, close to pointless for the weekly agents, and it multiplies handling opportunities either way.
Each additional injection is an additional stopper entry, an additional needle and an additional opportunity to introduce contamination into a preparation that has no release testing behind it.
On the detail: accumulation to steady state takes four to five half-lives regardless of how the dose is divided. Splitting does not shorten it and does not change the average exposure.
The peak-to-trough relationship 2^(τ/t½) is standard pharmacokinetics for a one-compartment model with first-order elimination and is the correct tool for this question.
The caveat is that no split schedule has been evaluated in a trial, so the whole discussion is inference plus report.
Slower titration has evidence; splitting has anecdote. Prefer the first.
edited 14 Dec 2024 by gunnar_isaksen — tightened the wording; no substantive change
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe honest answer is that reported tolerability benefits are real to the people reporting them and are not well explained by the exposure profile.
For a thirteen-hour half-life agent dosed daily, τ/t½ is about 1.8 and the swing is nearly fourfold, which is why the daily agents feel peakier and why splitting them would have more effect.
Worth being precise here: splitting that same weekly dose into two half-doses at 3.5-day intervals gives τ/t½ = 0.5 and a peak-to-trough ratio of about 1.41. The profile is flatter, and the difference between a 2-fold and a 1.4-fold swing is not obviously perceptible.
Titration schedules in the trial programmes were designed to manage gastrointestinal tolerability and are the evidenced approach to that problem.
More injections means more handling risk, and that cost is certain while the benefit is not.
If you cannot read half the dose accurately, you cannot split it accurately.
Answer first: splitting a weekly dose into smaller more frequent doses reduces peak-to-trough variation, and whether that helps depends entirely on the half-life of the agent.
For a drug with elimination half-life t½ dosed at interval τ, the peak-to-trough ratio at steady state is 2^(τ/t½). With a one-week half-life dosed weekly, τ/t½ = 1, so the ratio is 2 — a factor of two between peak and trough, which is already flat by pharmacological standards.
A slower titration achieves a lower peak exposure with fewer handling steps, which is why it is the better-evidenced answer to the same problem.
Halving a dose you cannot read accurately introduces an error larger than the effect you are chasing.
Work out 2^(τ/t½) for your agent before arguing about this. It usually settles it.
The relevant arithmetic is the accumulation ratio, which tells you how flat the profile already is at the current interval.
Reported tolerability improvements with splitting may reflect the smaller absolute amount arriving at once rather than the exposure profile, which is a different mechanism and is not well characterised.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Every split is another stopper entry. Count that cost.
Every split doubles the number of stopper entries and injections, which is a real cost against an uncertain benefit.
Halving a dose accurately requires the reading resolution to support it. A 10-unit dose split into two 5-unit doses is at the coarse end of any barrel.
For a weekly half-life, weekly dosing is already flat. Splitting buys very little.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.